Senti Virus

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Senti Bioscience, Inc. (SNTI) Investigation

Retrieved on: 
Tuesday, February 21, 2023

The investigation concerns whether Dynamics Special Purpose Corp. failed to provide relevant information to its shareholders before the merger.

Key Points: 
  • The investigation concerns whether Dynamics Special Purpose Corp. failed to provide relevant information to its shareholders before the merger.
  • If you are aware of any facts relating to this investigation or hold Senti shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/snti .
  • You can also contact Peretz Bronstein or his Law Clerk and Clients Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

Senti Biosciences Announces New Employment Inducement Grants

Retrieved on: 
Friday, February 3, 2023

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced that effective on February 1, 2023, the Compensation Committee of Senti Bio’s Board of Directors granted to 13 new employees stock options to purchase an aggregate of 309,000 shares of the Company’s common stock with a per share exercise price of $1.81.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced that effective on February 1, 2023, the Compensation Committee of Senti Bio’s Board of Directors granted to 13 new employees stock options to purchase an aggregate of 309,000 shares of the Company’s common stock with a per share exercise price of $1.81.
  • These awards were made under the Company’s 2022 Inducement Equity Plan (the Plan).
  • The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan.
  • The Plan was adopted by the Company’s board of directors on August 5, 2022.

Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022

Information about the poster sessions is as follows:

Key Points: 
  • Information about the poster sessions is as follows:
    Following the presentations, copies of the posters will be available on the Scientific Presentations & Publications section of the Senti Bio website.
  • 333-267390), filed with the SEC on September 12, 2022, and other documents filed by Senti Bio from time to time with the SEC.
  • Senti Bio anticipates that subsequent events and developments may cause Senti Bios assessments to change.
  • Availability of Other Information About Senti Biosciences, Inc.
    For more information, please visit the Senti Bio website at https://www.sentibio.com or follow Senti Bio on Twitter (@SentiBio) and LinkedIn (Senti Biosciences).